Liver lymphoma

Summary

Liver lymphoma (MONDO:0004695) is a cancer and 1 clinical trial. Top therapeutic interventions include acalabrutinib, bendamustine, and rituximab. A subtype of liver cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	liver lymphoma
Mondo ID	MONDO:0004695
DOID	DOID:901
NCIT	C4949
UMLS	C1112746
MedGen	207276
GARD	0024089
Anatomy (UBERON)	UBERON:0002107
Is cancer (heuristic)	yes

Also known as: hepatic lymphoma · liver lymphoma · lymphoma of liver · lymphoma of the liver · primary hepatic lymphoma · primary liver lymphoma

Disease family

This is a subtype of liver cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › digestive system cancer › liver cancer › liver lymphoma

Related subtypes (4): liver sarcoma, biliary tract cancer, calcifying nested epithelial stromal tumor of the liver, carcinoma of liver and intrahepatic biliary tract

Subtypes (1): liver diffuse large B-cell lymphoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04115631	PHASE2	ACTIVE_NOT_RECRUITING	A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ACALABRUTINIB	4	1
BENDAMUSTINE	4	1
RITUXIMAB	4	1
CHEMBL4747506	0	1
CHEMBL5187554	0	1
CHEMBL5276925	0	1